Literature DB >> 7697732

Ecto-5'-nucleotidase activity is not required for T cell activation through CD73.

W Gutensohn1, R Resta, Y Misumi, Y Ikehara, L F Thompson.   

Abstract

It had previously been shown that CD73 (ecto-5'-nucleotidase) expressed on 30% of normal human peripheral T-lymphocytes can mediate costimulatory signals in T cell activation. To check for a possible contribution of the catalytic property of CD73 to this function transfected cell lines were created. Using site-directed mutagenesis on human CD73 cDNA the codons of His92 and His194 were exchanged for alanine codons. Wild type and mutant cDNAs were cloned into an expression vector and stably expressed in the T cell line Jurkat. Surface expression as quantitated by immunofluorescence with anti CD73 mAbs was comparable in wild type and mutant transfectant clones, whereas in contrast to the wild type both His to Ala mutants completely lacked enzymatic activity. The Jurkat transfectants were stimulated with a combination of soluble anti-CD73 mAb and PMA and their response was quantitated by IL-2 production. The responses of different clones of wild type and mutant transfectants varied within a wide range; however, the ranges of wild type and mutants overlap. It is concluded that in order to transmit costimulatory signals CD73 does not require its catalytic activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7697732     DOI: 10.1006/cimm.1995.1029

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  8 in total

1.  Phosphate starvation-inducible gene ushA encodes a 5' nucleotidase required for growth of Corynebacterium glutamicum on media with nucleotides as the phosphorus source.

Authors:  Doris Rittmann; Ulrike Sorger-Herrmann; Volker F Wendisch
Journal:  Appl Environ Microbiol       Date:  2005-08       Impact factor: 4.792

2.  Upregulation of CD73 Confers Acquired Radioresistance and is Required for Maintaining Irradiation-selected Pancreatic Cancer Cells in a Mesenchymal State.

Authors:  Anna M Nguyen; Jianhong Zhou; Brihget Sicairos; Sangeetha Sonney; Yuchun Du
Journal:  Mol Cell Proteomics       Date:  2019-12-26       Impact factor: 5.911

Review 3.  Cellular function and molecular structure of ecto-nucleotidases.

Authors:  Herbert Zimmermann; Matthias Zebisch; Norbert Sträter
Journal:  Purinergic Signal       Date:  2012-05-04       Impact factor: 3.765

4.  Differential regulation and function of CD73, a glycosyl-phosphatidylinositol-linked 70-kD adhesion molecule, on lymphocytes and endothelial cells.

Authors:  L Airas; J Niemelä; M Salmi; T Puurunen; D J Smith; S Jalkanen
Journal:  J Cell Biol       Date:  1997-01-27       Impact factor: 10.539

5.  CD73 participates in cellular multiresistance program and protects against TRAIL-induced apoptosis.

Authors:  Andrey Mikhailov; Alice Sokolovskaya; Gennady G Yegutkin; Hanne Amdahl; Anne West; Hideo Yagita; Riitta Lahesmaa; Linda F Thompson; Sirpa Jalkanen; Dmitry Blokhin; John E Eriksson
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

6.  Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.

Authors:  Paul A Beavis; Upulie Divisekera; Christophe Paget; Melvyn T Chow; Liza B John; Christel Devaud; Karen Dwyer; John Stagg; Mark J Smyth; Phillip K Darcy
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-20       Impact factor: 11.205

7.  Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia.

Authors:  Linda F Thompson; Holger K Eltzschig; Juan C Ibla; C Justin Van De Wiele; Regina Resta; Julio C Morote-Garcia; Sean P Colgan
Journal:  J Exp Med       Date:  2004-12-06       Impact factor: 14.307

8.  A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes.

Authors:  Alberto L Horenstein; Antonella Chillemi; Gianluca Zaccarello; Santina Bruzzone; Valeria Quarona; Andrea Zito; Sara Serra; Fabio Malavasi
Journal:  Oncoimmunology       Date:  2013-09-26       Impact factor: 8.110

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.